

Clinical trials of renin inhibitor for hypertension in all type of patients

TrialResults-center www.trialresultscenter.org

1 direct renin inhibitor

Trial	Treatments	Patients	Trials design and methods
aliskiren vs ramipril			
Andersen , 2008 n=NA follow-up: 26 weeks	aliskiren 150 mg (up to 300mg) daily versus ramipril 5 mg (up to 10mg) daily	-	Parallel groups double blind

References

Andersen, 2008:

Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, Keefe DL Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99 [[18300872](#)]

2 direct renin inhibitor

Trial	Treatments	Patients	Trials design and methods
aliskiren vs placebo			
AVOID , 2008 [NCT00097955] n=301/298 follow-up: 6 months	aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months versus placebo	patients with hypertension and type 2 diabetes with nephropathy	Parallel groups double blind 15 countries
aliskiren vs hydrochlorothiazide			
Schmieder (vs HCTZ) , 2009 n=567/557 follow-up: 20 weeks	aliskiren 300 mg versus hydrochlorothiazide 25 mg	patients with essential hypertension	Parallel groups double blind
aliskiren vs losartan			
ALLAY , 2009 [NCT00219141] n=154/152 follow-up: 9 months	aliskiren 300 mg versus losartan 100 mg	patients with hypertension, increased ventricular wall thickness, and body mass index >25 kg/m ²	Parallel groups open

References

AVOID, 2008:

Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46 [[18525041](#)]

Schmieder (vs HCTZ), 2009:

Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation* 2009;119:417-25 [[19139391](#)]

ALLAY, 2009:

Solomon SD, Appelbaum E, Manning WJ, Verma A, Berglund T, Lukashevich V, Cherif Papst C, Smith BA, Dahlf B Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. *Circulation* 2009;119:530-7 [[19153265](#)]

3 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.